This is in large part due to an overly superficial examination of the mutations, i.e., by limiting mutation analyses to those exons that encode the DNA binding domain, or by inferring mutation status by immunohistochemistry, which detects tumor cells harboring stable mutant p53 protein but does not readily distinguish those harboring p53 null variants from wild-type variants. This evidence concerns the gene TP53 and neoplasm.